Peter C. Adamson

16.4k total citations · 3 hit papers
238 papers, 11.3k citations indexed

About

Peter C. Adamson is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Peter C. Adamson has authored 238 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 69 papers in Oncology and 64 papers in Neurology. Recurrent topics in Peter C. Adamson's work include Neuroblastoma Research and Treatments (59 papers), Acute Lymphoblastic Leukemia research (55 papers) and Cancer therapeutics and mechanisms (39 papers). Peter C. Adamson is often cited by papers focused on Neuroblastoma Research and Treatments (59 papers), Acute Lymphoblastic Leukemia research (55 papers) and Cancer therapeutics and mechanisms (39 papers). Peter C. Adamson collaborates with scholars based in United States, Canada and United Kingdom. Peter C. Adamson's co-authors include Susan M. Blaney, Brigitte C. Widemann, Frank M. Balis, Mark Krailo, Ashish M. Ingle, Gregory H. Reaman, Elizabeth Fox, Brenda J. Weigel, Stephan D. Voss and Joel M. Reid and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Peter C. Adamson

237 papers receiving 11.1k citations

Hit Papers

Understanding and Managing Methotrexate Nephrotoxicity 2006 2026 2012 2019 2006 2013 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Understanding and Managing Methotrexate Nephrotoxicity
    2006 533 citations Brigitte C. Widemann, Peter C. Adamson profile →
  2. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    2013 477 citations Yaël P. Mossé, Stephan D. Voss et al. profile →
  3. Declining childhood and adolescent cancer mortality
    2014 363 citations Malcolm A. Smith, Peter C. Adamson et al. profile →

Peers

Peter C. Adamson
Comparison fields: 5 of 156
  • Molecular Biology 3.5k
  • Oncology 2.7k
  • Pulmonary and Respiratory Medicine 2.2k
  • Public Health, Environmental and Occupational Health 2.2k
  • Neurology 2.2k
Replace Frank M. Balis with:
Frank M. Balis United States
Gilles Vassal France
Gregory H. Reaman United States
David G. Poplack United States
Henk‐Jan Guchelaar Netherlands
Lawrence H. Einhorn United States
Lisa Rybicki United States
Eve Roman United Kingdom
Leontien C.M. Kremer Netherlands
Patrick J. Loehrer United States
Frank M. Balis United States View profile →
Citations per field, relative to Peter C. Adamson
Peter C. Adamson · 1×
Citations per year, relative to Peter C. Adamson
Peter C. Adamson · 1×

Countries citing papers authored by Peter C. Adamson

Since Specialization
Citations

This map shows the geographic impact of Peter C. Adamson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter C. Adamson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter C. Adamson more than expected).

Fields of papers citing papers by Peter C. Adamson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter C. Adamson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter C. Adamson. The network helps show where Peter C. Adamson may publish in the future.

Co-authorship network of co-authors of Peter C. Adamson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter C. Adamson. A scholar is included among the top collaborators of Peter C. Adamson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter C. Adamson. Peter C. Adamson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Heart Failure Hospitalisation Reduction With Remote Pulmonary Artery Pressure Monitoring in Australia: Results of the CardioMEMS HF System OUS Post-Market Study
2024 ·Heart Lung and Circulation ·S. McKenzie, (unknown), David O’Donnell, Carlo Gazzola, Peter C. Adamson
1
2
Model‐Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy
2023 ·Clinical Pharmacology & Therapeutics ·Kana Mizuno, Edmund V. Capparelli, Tsuyoshi Fukuda, Min Dong, Peter C. Adamson, (unknown), Avital Cnaan, Peggy O. Clark, Michael D. Reed, Shlomo Shinnar, Alexander A. Vinks, Tracy A. Glauser, (unknown)
2
3
Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus
2023 ·Clinical Pharmacology & Therapeutics ·Teresa de Rojas, (unknown), Andrew D.J. Pearson, (unknown), Peter C. Adamson, Hubert Caron, Gilles Vassal
0
4
My Patient Portal
2022 ·Annals of Internal Medicine ·Peter C. Adamson
1
5
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
2021 ·Clinical Cancer Research ·Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé
61
6
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report
2021 ·Neuro-Oncology ·Jack Su, Lindsay Kilburn, David B. Mansur, Mark Krailo, Allen Buxton, (unknown), Amar Gajjar, Peter C. Adamson, Brenda J. Weigel, Elizabeth Fox, Susan M. Blaney, Maryam Fouladi
39
7
Pediatric cancer research: Surviving COVID‐19
2020 ·Pediatric Blood & Cancer ·Jeffery J. Auletta, Peter C. Adamson, (unknown), Pamela Kearns, Scott R. Kennedy, Mark W. Kieran, (unknown), (unknown), (unknown), (unknown), Carol J. Thiele, Timothy P. Cripe
24
8
Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events
2019 ·Pediatric Blood & Cancer ·Tamara P. Miller, Brian T. Fisher, Kelly Getz, (unknown), Hanieh Razzaghi, Alix E. Seif, Rochelle Bagatell, Peter C. Adamson, Richard Aplenc
39
9
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear‐medicine‐based estimates of renal function
2019 ·Pediatric Blood & Cancer ·Peter C. Adamson, Gareth J. Veal, Richard B. Womer, Holly J. Meany, M. Brooke Bernhardt, A. Lindsay Frazier, Frank M. Balis
5
10
American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment
2014 ·Journal of Clinical Oncology ·Jeffrey S. Weber, Laura A. Levit, Peter C. Adamson, Suanna S. Bruinooge, Howard A. Burris, Michael A. Carducci, Adam P. Dicker, Mithat Gönen, Stephen J. O’Keefe, Michael A. Postow, Michael A. Thompson, David Waterhouse, Susan Weiner, Lynn M. Schuchter
81
11
A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma
2014 ·Journal of Chromatography B ·Ganesh S. Moorthy, Robin E. Norris, Peter C. Adamson, Elizabeth Fox
1
12
Evaluation of the Retinoids With Cisplatin and Vincristine in Xenograft Models of Neuroblastoma
2013 ·Journal of Pediatric Hematology/Oncology ·Robin E. Norris, Vu Thuong Nguyen, Peter C. Adamson
2
13
A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
2012 ·Clinical Cancer Research ·Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda J. Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney
90
14
A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report
2012 ·Clinical Cancer Research ·Julia Glade Bender, Susan M. Blaney, Scott C. Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte H. Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice P. Chen, Brenda J. Weigel, Peter C. Adamson, Julie R. Park
16
15
Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
2011 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll, Charles T. Roberts, Joel M. Reid, Stephen C. Schmechel, Stephan D. Voss, (unknown), Helen X. Chen, Mark Krailo, Peter C. Adamson, Susan M. Blaney
147
16
Behavior and quality of life in Childhood Absence Epilepsy (CAE) - Baseline data from the NIHCAE trial
2006 ·Data Archiving and Networked Services (DANS) ·Christine O’Dell, Shlomo Shinnar, Avital Cnaan, David Masur, Mayadah Shabbout, Paul M. Levisohn, Deborah Hirtz, Peter C. Adamson, (unknown), null null
1
17
Potentiation of cytotoxic drugs with concomitant exposure to retinoids in neuroblastoma
2006 ·Cancer Research ·Peter C. Adamson, (unknown)
2
18
The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function
2004 ·Critical Care Medicine ·Athena F. Zuppa, Vinay Nadkarni, Lauren Davis, Peter C. Adamson, Mark A. Helfaer, Michael R. Elliott, John Abrams, Dennis R. Durbin
72
19
Dose-Dependent Pharmacokinetics of All-trans-Retinoic Acid
1992 ·JNCI Journal of the National Cancer Institute ·Peter C. Adamson, Frank M. Balis, (unknown), Robert F. Murphy, (unknown), (unknown)
32
20
Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.
1992 ·Journal of Clinical Oncology ·Malcolm A. Smith, Peter C. Adamson, Frank M. Balis, James H. Feusner, (unknown), Robert F. Murphy, Marc E. Horowitz, Gregory H. Reaman, G. Denman Hammond, (unknown)
119

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank M. Balis Breakdown of academic impact, for papers by Gilles Vassal Breakdown of academic impact, for papers by Gregory H. Reaman Breakdown of academic impact, for papers by David G. Poplack Breakdown of academic impact, for papers by Henk‐Jan Guchelaar Breakdown of academic impact, for papers by Lawrence H. Einhorn Breakdown of academic impact, for papers by Lisa Rybicki Breakdown of academic impact, for papers by Eve Roman Breakdown of academic impact, for papers by Leontien C.M. Kremer Breakdown of academic impact, for papers by Patrick J. Loehrer
Rankless by CCL
2026